NADH:ubiquinone oxidoreductase subunit B6Genealiases: B17 · CI
Q-omics provides the consensus-scored NDUFB6 profile across patient tissues and cancer cell-line models. NDUFB6 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFB6 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, NDUFB6 protein abundance shows 25,188 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, LIHC, and GBM as cancer lineages where NDUFB6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFB6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFB6 survival associations across molecular data types. NDUFB6 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFB6 RNA expression–survival associations across cancer types. High NDUFB6 expression shows unfavorable associations in UVM and HNSC, but favorable associations in KIRC, COAD, OV and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFB6 RNA expression.
This table summarizes NDUFB6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFB6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFB6 shows lower tumor expression in THCA and KIRC and higher tumor expression in LIHC, BRCA, HNSC and CHOL. The LIHC box plot shows higher NDUFB6 RNA expression in tumor versus normal tissue (log2 FC = +0.711, t-test p < 0.001).
This table shows molecular features associated with NDUFB6 in patient tissues and cancer cell lines. In patient samples, NDUFB6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFB6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
